G E Y U A N 格 远 律 师 事 务 所 Firm 关于山西锦波生物医药股份有限公司 2025 年第四次临时股东会的 法律意见书 山两校 93 山西格远律师事务所 关于山西锦波生物医药股份有限公司 2025 年第四次临时股东会的 法律意见书 致:山西锦波生物医药股份有限公司 根据《中华人民共和国证券法(2019年修订)》(以下简称"《证券法》")《中 华人民共和国公司法(2023年修正)》(以下简称"《公司法》")《北京证券交易 所上市公司持续监管办法》《上市公司信息披露管理办法》等法律、法规和其他 有关规范性文件的要求,山西格远律师事务所(以下简称"本所")接受山西锦 波生物医药股份有限公司(以下简称"锦波生物"或"公司")的委托,指派律 师参加公司 2025年第四次临时股东会(以下简称"本次股东会"或"本次会议")。 为出具本《法律意见书》,本所声明如下: 1、本所律师仅对本次股东会的召集程序、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果及会议决议发表法律意见,并不对本次股东会 所审议的议案、议案所涉及的数字及内容发表意见。 2、本所及经办律师依据《证券法》《律师事务所从事证券法 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-154 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东会届次 本次会议为 2025 年第五次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 2025 年 9 月 8 日，公司第四届董事会第十五次会议审议通过了《关于提请 召开公司 2025 年第五次临时股东会的议案》。 山西锦波生物医药股份有限公司 关于召开 2025 年第五次临时股东会通知公告（提供网络投票） （三）会议召开的合法合规性 本次股东会的召集、召开所履行的程序符合《公司法》和《公司章程》的有 关规定。会议召开无需相关部门批准或履行必要程序。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东只能选择现场投票、网络投票中的一种方式，如果同一表决 票出现重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 9 月 24 日 14:30。 2、网络投票起止时间 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-149 山西锦波生物医药股份有限公司 第四届董事会第十五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 9 月 8 日 2.会议召开地点：公司三楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 9 月 6 日以邮件方式发出 5.会议主持人：董事长杨霞女士 董事王玲玲、阎丽明、梁桐栋、张金鑫因出差或外地办公以通讯方式参与表 决。 二、议案审议情况 （一）审议通过《关于聘任杨霞女士为公司总经理的议案》 1.议案内容： 根据《公司法》《公司章程》等相关规定，经公司董事会提名，现聘任杨霞 女士为公司总经理，任期自本次董事会审议通过之日起至第四届董事会届满之日 止。 6.会议列席人员：薛芳琴、兰小宾 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、 ...

报告要点 [Table_Summary] 公司发布 2025 年半年报，2025H1 实现营收 8.59 亿元，同比增长 42.43%；归母净利润 3.92 亿元，同比增长 26.65%。单二季度，公司实现营收 4.92 亿元，同比增长 30.44%；归母净利 润 2.24 亿元，同比增长 7.4%。 分析师及联系人 [Table_Author] 丨证券研究报告丨 公司研究丨点评报告丨锦波生物（832982.BJ） [Table_Title] 锦波生物 2025 年中报点评：收入韧性凸显，凝 胶贡献第二增长曲线 SAC：S0490514080004 SAC：S0490520080019 SFC：BUV258 李锦 罗祎 曾维朵 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 锦波生物（832982.BJ） cjzqdt11111 [Table_Title 锦波生物 2025 2] 年中报点评：收入韧性凸显，凝 胶贡献第二增长曲线 [Table_Summary2] 事件描述 公司发布 2025 年半年报，2025H1 实现营收 8.59 亿元，同比增长 42.43 ...

Group 1 - The financing balance of the Beijing Stock Exchange (BSE) reached a new high of 7.364 billion yuan as of September 4, 2025, indicating strong market resilience and investor confidence [1][9][22] - The financing balance of the BSE has shown a consistent upward trend, with significant increases observed during three market rallies in November 2023, September 2024, and February 2025 [1][11][14] - The proportion of financing balance to market capitalization for the BSE is 1.17%, significantly lower than that of the Sci-Tech Innovation Board (2.90%) and the Growth Enterprise Market (3.49%), suggesting potential for future growth in financing [1][14][15] Group 2 - The BSE's average daily trading volume reached 35.971 billion yuan, a 7.82% increase from the previous week, reflecting improved liquidity in the market [2][26][28] - The BSE 50 Index closed at 1,618.18 points with a TTM PE ratio of 79.12, indicating a solid valuation level [2][27][29] - The top three companies by financing balance on the BSE are Jinbo Biological, Better Ray, and Shuguang Digital, with financing balances of 327 million yuan, 270 million yuan, and 230 million yuan respectively [18][22][23] Group 3 - The report highlights the performance of various sectors, with the TTM PE ratios for high-end equipment, information technology, new chemical materials, consumer services, and pharmaceutical biology being 46.83, 110.99, 51.38, 63.12, and 48.25 respectively [2][37][39] - The report suggests focusing on technology growth, self-sufficiency, anti-involution, and energy storage sectors following the release of semi-annual reports [2][41][42] - The report indicates that the number of companies with a TTM PE ratio exceeding 45 has increased, with 158 companies now in this category, reflecting a shift in valuation structure [2][31][35]

Group 1 - The medical beauty sector experienced a rise of 3.39% on September 5, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 190.83, up 3.67%, and Huaxi Biological closing at 57.14, up 3.23% [1] Group 2 - The medical beauty sector saw a net inflow of 36.38 million yuan from institutional investors, while retail investors experienced a net outflow of 44.71 million yuan [1] - The trading volume for Ai Meike was 45,900 hands, with a transaction amount of 858 million yuan [1] - The stock performance of other companies in the sector included *ST Meigu, which closed at 3.17, up 0.63%, and Jinbo Biological, which closed at 302.39, down 0.86% [1]

Market Overview - The medical beauty sector experienced a decline of 1.3% on September 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Individual Stock Performance - ST Meigu closed at 3.15, with a slight increase of 0.32% and a trading volume of 95,700 shares, amounting to a transaction value of 30.34 million yuan [1] - Huaxi Biological closed at 55.35, down 0.66%, with a trading volume of 46,700 shares and a transaction value of 25.9 million yuan [1] - Aimeike closed at 184.07, down 1.83%, with a trading volume of 41,200 shares and a transaction value of 763 million yuan [1] - Jinbo Biological closed at 305.00, down 3.81%, with a trading volume of 9,732.97 shares and a transaction value of 301 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 58.64 million yuan from institutional investors, while retail investors had a net inflow of 24.48 million yuan [1] - The overall capital flow indicates a mixed sentiment, with retail investors showing some interest despite the institutional outflow [1]

Group 1 - The core viewpoint of the articles highlights the positive performance of companies listed on the Beijing Stock Exchange (北交所), with 274 companies reporting over 6% year-on-year revenue growth in the first half of the year, outperforming the overall A-share market [1] - In the second quarter, Beijing Stock Exchange companies achieved a total revenue of 50.547 billion yuan, representing a quarter-on-quarter growth of 21.75%, and a net profit of 3.133 billion yuan, with a quarter-on-quarter increase of 12.88% [1] - The top 50 companies by market capitalization on the Beijing Stock Exchange generated a total revenue of 37.474 billion yuan in the first half, with a year-on-year growth of 6.97%, and a net profit of 3.214 billion yuan, reflecting a year-on-year increase of 2.66% [1] Group 2 - Over 20 companies on the Beijing Stock Exchange plan to distribute mid-term dividends, with Jinbo Biological (锦波生物) proposing a cash dividend of 10 yuan per 10 shares, amounting to a total dividend of 115 million yuan [2] - The outlook for the Beijing Stock Exchange suggests a focus on technology growth, self-sufficiency, and sectors such as military and specialized small giant companies, which represent new productive forces [2] - Investment strategies for the second half of the year recommend focusing on new productive sectors like artificial intelligence and new consumption, as well as selecting companies based on financial metrics that show high growth potential and strong R&D investment [2]

Core Viewpoint - The A-share market shows a mixed performance with the Shanghai Composite Index closing above the six-month moving average, indicating potential bullish sentiment among investors [1] Group 1: Market Overview - As of 13:59 today, the Shanghai Composite Index stands at 3814.20 points, with a decline of 1.14% [1] - The total trading volume in the A-share market reached 1,878.28 billion yuan [1] Group 2: Stocks Breaking the Six-Month Moving Average - Thirteen A-shares have surpassed the six-month moving average today, with notable stocks including Renfu Pharmaceutical, Guofeng New Materials, and Zhizheng Co., which have deviation rates of 8.65%, 4.92%, and 4.08% respectively [1] - Stocks with smaller deviation rates that have just crossed the six-month moving average include Jinbo Biological, ST Huawen, and *ST Zhongzhuang [1] Group 3: Individual Stock Performance - Renfu Pharmaceutical (600079) experienced a price increase of 9.99% with a turnover rate of 8.87%, closing at 22.57 yuan, showing a deviation rate of 8.65% from the six-month moving average [1] - Guofeng New Materials (000859) rose by 6.13% with a turnover rate of 9.75%, closing at 7.10 yuan, reflecting a deviation rate of 4.92% [1] - Zhizheng Co. (603991) saw a 4.74% increase with a turnover rate of 4.15%, closing at 63.48 yuan, with a deviation rate of 4.08% [1]

Core Viewpoint - The performance of listed medical beauty companies in China shows significant divergence in the first half of 2025, with major players in the hyaluronic acid market facing growth bottlenecks, while companies in the recombinant collagen segment are experiencing substantial growth [1][2][7]. Group 1: Performance of Major Companies - Huaxi Biological reported revenue of 2.261 billion yuan, a year-on-year decline of 19.57%, and a net profit of 221 million yuan, down 35.38% [1][2]. - Haohai Biological achieved revenue of 1.304 billion yuan, a decrease of 7.12%, with a net profit of 211 million yuan, down 10.29% [1][2]. - Aimeike's revenue was 1.299 billion yuan, down 21.59%, with a net profit of 789 million yuan, a decline of 29.57% [1][2]. - In contrast, Jinbo Biological, the first stock of recombinant collagen on the Beijing Stock Exchange, reported revenue of 859 million yuan, an increase of 42.43%, and a net profit of 392 million yuan, up 26.65% [1][2]. - Giant Biological's revenue reached 3.113 billion yuan, a year-on-year increase of 21.66%, with a net profit of 1.182 billion yuan, up 20.23% [1][2]. Group 2: Market Trends and Competition - The medical beauty market in China has seen rapid growth, with the market size increasing from 99.3 billion yuan in 2017 to 189.2 billion yuan in 2021, reflecting a compound annual growth rate of 17.5% [4]. - The competition in the hyaluronic acid sector has intensified, leading to price reductions and impacting the performance of leading companies [4][6]. - The demand for aesthetic products is evolving, with a shift towards user-oriented solutions and a growing emphasis on product innovation and technology [3][7]. Group 3: Strategic Adjustments and Innovations - Huaxi Biological is shifting its marketing strategy to focus on brand building and consumer engagement through platforms like Xiaohongshu and WeChat, moving away from price-driven promotions [5]. - Haohai Biological is also adapting its product offerings, with new high-end hyaluronic acid products showing promising market performance [6]. - The recombinant collagen market is projected to grow significantly, with estimates suggesting it will reach 585.7 billion yuan by 2025, driven by new product launches and market expansion [8][9]. Group 4: Regulatory and International Expansion - The medical beauty industry is witnessing an increase in compliant products, with several companies obtaining third-class medical device registration certificates, enhancing market offerings [10][11]. - Companies like Huaxi Biological and Haohai Biological are actively pursuing international markets, with Huaxi reporting significant revenue from overseas operations [11][12]. - Aimeike's acquisition of a majority stake in a South Korean company highlights the trend of domestic firms expanding their global footprint [12].